Agenus Aims for Phase 3 Trial in Colon Cancer as Funding Depends on Enrollment

November 5, 2026 - 18:37

Agenus plans to start patient enrollment in the coming months for a Phase 3 trial of its investigational immunotherapy combination BOT/BAL aimed at treating early-stage colon cancer. During a recent investor event, company executives outlined their strategy for the study, named ROBIN, which is set to include around 850 patients diagnosed with high-risk stage II colon cancer.

The trial is crucial for Agenus as its financing is closely tied to meeting specific enrollment milestones. The company is optimistic about the potential of BOT/BAL, which combines two therapeutic agents designed to enhance the immune system's ability to target and destroy cancer cells. This approach represents a significant advancement in the treatment of colon cancer, a condition that continues to affect a large number of patients worldwide.

As the trial progresses, Agenus is focused on demonstrating the efficacy and safety of its treatment, hoping to contribute to improved outcomes for patients facing this challenging disease. The upcoming months will be pivotal for the company as it works to secure the necessary funding and move forward with its clinical objectives.